Diarrhea News and Research

Latest Diarrhea News and Research

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.

21 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Unprescribed methods to bring on labor may not be effective

More than half of the women in a recently published survey reported that near the end of their pregnancies, they took it upon themselves to try to induce labor, mostly by walking, having sex, eating spicy food or stimulating their nipples.

17 Jun 2011

UTHealth receives $1M FEMA grant to examine link between Ad-36 infection, obesity

Researchers at The University of Texas Health Science Center at Houston (UTHealth) have been awarded nearly $1 million to investigate Adenovirus-36 (Ad-36) infection as a novel risk factor for obesity.

17 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Intralytix, Inc. announced today that it has completed regulatory clearance from both the Food and Drug Administration (FDA) and the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

15 Jun 2011

Colonoscopies done with suboptimal bowel preparation linked to high adenoma miss rates

A new study reports that colonoscopies done with suboptimal bowel preparation are associated with relatively high adenoma (precancerous polyp) miss rates, suggesting that suboptimal bowel preparation substantially decreases colonoscopy effectiveness and may mandate an early follow-up examination.

14 Jun 2011

Billions committed for children’s vaccines

British Prime Minister David Cameron has pledged £814m to help vaccinate children around the world against preventable diseases like pneumonia. He made the announcement at a summit in London where countries are being asked to give an extra £2.3bn ($3.7bn) by 2015 for child vaccines. He said, “Three children die every minute from pneumonia alone. Waiting is not the right thing to do and I don't think that 0.7 per cent of our gross national income is too high a price to pay for saving lives.”

13 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin Pharmaceuticals, Inc. today issued the following statement regarding the decision of the United States District Court for the Southern District of California to deny its motion for a preliminary injunction to enjoin Eli Lilly and Company from engaging in anticompetitive activity and breaching its diabetes collaboration agreement with Amylin.

10 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.

7 Jun 2011

Diarrhea News and Research

Latest Diarrhea News and Research

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

FDA approves NULOJIX

Unprescribed methods to bring on labor may not be effective

UTHealth receives $1M FEMA grant to examine link between Ad-36 infection, obesity

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Intralytix obtains FDA, FSIS regulatory clearance for bacteriophage-based product against E. coli

Colonoscopies done with suboptimal bowel preparation linked to high adenoma miss rates

Billions committed for children’s vaccines

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in